Briacell Therap (NASDAQ:BCTX) Trading 3.7% Higher – Here’s What Happened

Briacell Therap (NASDAQ:BCTX)’s stock price traded up 3.7% on Tuesday . The company traded as high as $10.01 and last traded at $10.00. 13,978 shares changed hands during trading, a decline of 65% from the average session volume of 40,477 shares. The stock had previously closed at $9.64.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $320.00.

Briacell Therap Trading Up 3.7%

The stock’s 50-day moving average is $10.97 and its 200-day moving average is $15.69. The stock has a market cap of $18.80 million, a price-to-earnings ratio of -0.12 and a beta of 1.38.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new position in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.